Streetbeat News

Price Targets

IBTA

JMP Securities analyst Andrew Boone maintains a Market Outperform rating on Ibotta (NYSE:IBTA) but lowers the price target from $130 to $111.

Portfolio Pulse from Benzinga Newsdesk

August 14, 2024 | 5:52 pm

FLUT

JMP Securities has maintained a Market Outperform rating on Flutter Entertainment (NYSE:FLUT) and raised the price target from $246 to $255.

Portfolio Pulse from Benzinga Newsdesk

August 14, 2024 | 5:50 pm

HD

IEDI

XLY

Home Depot's (NYSE:HD) price forecasts for 2024 have been lowered by several analysts following modest sales growth and a weaker consumer outlook. Despite reporting a slight sales increase and beating EPS estimates, analysts have cut price targets and revised earnings estimates downward. Investors can also gain exposure to Home Depot through ETFs like iShares U.S. Consumer Focused ETF (BATS:IEDI) and SPDR Select Sector Fund – Consumer Discretionary (NYSE:XLY).

Portfolio Pulse from Lekha Gupta

August 14, 2024 | 5:48 pm

MTH

Wolfe Research has upgraded Meritage Homes (NYSE:MTH) from Peer Perform to Outperform and set a price target of $230.

Portfolio Pulse from Benzinga Newsdesk

August 14, 2024 | 5:45 pm

MA

BMO Capital analyst Rufus Hone maintains an Outperform rating on Mastercard (NYSE:MA) with a $520 price target.

Portfolio Pulse from Benzinga Newsdesk

August 14, 2024 | 5:44 pm

AMWD

Wolfe Research has upgraded American Woodmark (NASDAQ:AMWD) from Peer Perform to Outperform, setting a price target of $110.

Portfolio Pulse from Benzinga Newsdesk

August 14, 2024 | 5:43 pm

SE

Wedbush analyst Scott Devitt maintains an Outperform rating on Sea (NYSE:SE) and raises the price target from $76 to $84.

Portfolio Pulse from Benzinga Newsdesk

August 14, 2024 | 5:40 pm

CNTA

Oppenheimer analyst Francois Brisebois has reiterated an Outperform rating on Centessa Pharmaceuticals (NASDAQ:CNTA) and maintained a $14 price target.

Portfolio Pulse from Benzinga Newsdesk

August 14, 2024 | 5:38 pm

PRAX

Wedbush analyst Laura Chico maintains a Neutral rating on Praxis Precision Medicine (NASDAQ:PRAX) and raises the price target from $40 to $48.

Portfolio Pulse from Benzinga Newsdesk

August 14, 2024 | 5:38 pm

RGLS

Oppenheimer analyst Andreas Argyrides has reiterated an Outperform rating on Regulus Therapeutics (NASDAQ:RGLS) and maintained a price target of $7.

Portfolio Pulse from Benzinga Newsdesk

August 14, 2024 | 5:36 pm